Understand the source comparison
Best Peptides for Sugar Cravings: Clinical Comparison
The table below compares the most clinically validated peptides for appetite and craving suppression based on mechanism, dosing, half-life, and documented efficacy. Semaglutide GLP-1 receptor agonist. Delays gastric emptying, suppresses ghrelin, extends PYY el
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares the most clinically validated peptides for appetite and craving suppression based on mechanism, dosing, half-life, and documented efficacy.
- Semaglutide
- GLP-1 receptor agonist. Delays gastric emptying, suppresses ghrelin, extends PYY elevation
- 0.25mg → 2.4mg weekly, titrated over 16–20 weeks
- ~7 days
- 68% reduction in food cravings at 68 weeks (STEP-1 trial)
- Gold standard for sustained appetite suppression with weekly dosing convenience
- Tirzepatide
- Dual GIP/GLP-1 receptor agonist. Combines incretin modulation with enhanced lipid metabolism
- 2.5mg → 15mg weekly, titrated over 20 weeks
- ~5 days
- Near-total elimination of sugar cravings by week 12 in SURMOUNT-1 Phase 3 trial
- Most potent option for weight loss and metabolic improvement. Dual receptor activation
- Liraglutide
- GLP-1 receptor agonist. Shorter half-life, daily injection
- 0.6mg → 3.0mg daily, titrated over 5 weeks
- ~13 hours
- 40–50% reduction in appetite scores at one year (SCALE trial)
- Effective but requires daily dosing. Better tolerated in patients sensitive to longer-acting GLP-1 agonists
- Tesofensine
- Monoamine reuptake inhibitor. Central appetite suppression, not incretin-mediated
- 0.25mg → 1.0mg daily
- ~60 hours
- Significant appetite suppression but higher side effect burden
- Not FDA-approved; psychiatric and cardiovascular monitoring required